What Is a Hemostatic Dressing? Agents, Evidence Tiers, and How to Verify Before You Buy

A hemostatic dressing is a carrier plus a chemical. The carrier is gauze, a patch, or granules. The chemical is an active hemostatic agent, and its job is to speed up clotting.

The U.S. Food and Drug Administration says the same thing in regulatory language. These devices go on the skin, from the outside. They control bleeding that is minor, moderate, or moderate-to-severe. They do it temporarily. And they normally work alongside manual compression rather than instead of it.

That definition hides the part that actually matters when you choose one. The dressing is not “better gauze.” It is a delivery system for a chemistry. Two products can look identical on a shelf. Both call themselves hemostatic. Both may be right about that. They can still work by different mechanisms, with very different evidence behind them.

Two people carry that risk. One writes the purchase order. The other decides what goes in the pouch. This guide is for them, and it does four things. It explains how the main agent families work. It separates the evidence tiers (CoTCCC-recommended, FDA-cleared, merely claimed). It shows how these dressings are applied and where they fail. And it closes with what to verify before one goes into a kit or a purchase order.

What a Hemostatic Dressing Actually Is

Strip the marketing off and every hemostatic dressing has two components:

1. A carrier — gauze (rolled or Z-folded), a non-woven patch, a sponge, or granules/powder with an applicator. The carrier’s job is mechanical: it gets the agent into or onto the wound, conforms to the wound shape, and gives you something to hold pressure with.
2. An active hemostatic agent — impregnated into or coated onto the carrier. This is the part that interacts with the clotting process. Without an active agent, you have ordinary gauze, no matter what the label says.

The FDA treats these as medical devices, not drugs. Its 2022 advisory panel materials on the Classification of Topical Hemostatic Wound Dressings set out the route. These products reach the market through the 510(k) pathway, under product code “FRO”. Over 100 have been cleared that way so far. The agency has also proposed regulating them as Class II devices with special controls (proposed regulation 21 CFR 878.4021).

Read the device description in those materials and it is more specific than most marketing pages. A topical hemostatic wound dressing is intended for external use. Its stated jobs are narrow: control bleeding, absorb wound exudate. It is normally an adjunct to manual compression, not a replacement for it. The FDA lists the physical forms explicitly: solid pads, sponges, granules, or gel. It draws the boundaries just as explicitly. These devices are not for use in the organ space, and not for placement next to internal tissues, veins, arteries, or nerves. Two smaller details are worth knowing. A dressing may contain antimicrobials such as chlorhexidine or silver. Those are not there to treat the wound. They protect the dressing itself: on the shelf, and during use. A dressing may also contain animal-derived materials such as collagen for structure or moisture retention. That becomes relevant when we get to risk assessment below.

One more classification detail deserves a pause. The version without thrombin is defined as containing no biologics and no antimicrobials with high antimicrobial-resistance risk. The agency deliberately separates plain-agent dressings from ones carrying biologically derived thrombin.

Two practical consequences follow. First, “hemostatic dressing” is a regulated device category with a specific intended use: temporary external bleeding control. Not a vague marketing term. Second, when a supplier says “FDA registered,” that is not the same as “FDA cleared.” Registration is a listing obligation. Clearance under a 510(k) means FDA reviewed substantial equivalence to a legally marketed predicate. For a buyer, only the second one is evidence.

How It Works: The Agent Does the Work

All clotting ends at the same place: fibrin mesh stabilizing a platelet plug. The agent families get there by different routes, and the route tells you the product’s strengths, failure modes, and storage constraints.

Kaolin: Contact Activation on a Shelf-Stable Mineral

Kaolin is an aluminosilicate clay. It activates the contact pathway of coagulation, classically described as activating Factor XII, which kicks off the intrinsic clotting cascade on the gauze surface. It works with the patient’s own clotting factors, needs no biological ingredients, and sits stable on the shelf. This is the mechanism behind the kaolin-impregnated gauze that the Committee on Tactical Combat Casualty Care (CoTCCC) named its hemostatic dressing of choice.

The dependency cuts both ways. Kaolin accelerates a cascade the patient supplies, so it needs that cascade to be functional, and it needs the gauze physically pressed against the bleeding vessel. Kaolin gauze laid on top of pooled blood does almost nothing. Packed to the source, it is a different device.

Pick the agent family from your storage reality rather than from the supplier’s datasheet. If the kit sits in a vehicle through a desert summer or in an unheated warehouse, the shelf-stable mineral and charge-based families absorb that abuse; a thrombin-bearing product is a cold-chain line item and should be quoted as one, with the supplier stating the storage envelope in writing before it enters a kit specification.

An older mineral agent, zeolite, worked partly by absorbing water and concentrating clotting factors, and partly by releasing heat. The exothermic reaction could burn tissue. First-generation zeolite products were reformulated and largely abandoned. That history is why “mineral-based” is not one category: the agent matters, not the family label.

Chitosan: A Charge-Based Seal That Skips the Cascade

A positive ionic charge does the work here. Chitosan, derived from chitin (the material of shellfish exoskeletons), binds to negatively charged red blood cells and tissue surfaces, forming a mucoadhesive physical seal over the wound. That mechanism works largely independently of the body’s clotting cascade. The independence is exactly why chitosan dressings are favored when clotting may be impaired, for example in patients on anticoagulation therapy, an indication that appears in FDA-cleared labeling for this device type.

The shellfish origin triggers an allergy question. The evidence has repeatedly not confirmed it as a clinical problem, because the reactive proteins are not in the purified chitosan. Expect the question from end users anyway, and have the answer ready.

Microporous Polysaccharide Hemospheres: Concentrating What Is Already There

The concentrating family takes a different road. Microporous polysaccharide hemospheres (MPH) are plant-based particles that act like molecular sieves: they pull water out of blood at the wound surface, concentrating platelets and clotting factors where they are needed. Same destination, different mechanism. Because the active material is a loose particle, the format depends on the wound containing it. That constraint returns in the safety section: loose agents entering a blood vessel are a named risk in FDA’s materials.

Thrombin and Fibrinogen: The Final Step, Pre-Packaged

The last family skips the cascade entirely. Thrombin is the enzyme that converts fibrinogen to fibrin, the final step of clotting, delivered pre-packaged. Fast, cascade-independent. But it is a biologic: the thrombin in these products is approved through a Biologic License Application (BLA), and it needs cold-chain or careful storage. That is why FDA splits the classification into “with licensed thrombin” and “without.” Of the devices the agency counts in this category, over 100 cleared products contain no thrombin and 18 contain licensed thrombin. The thrombin versions concentrate in clinical uses such as bleeding from vascular access sites, not field trauma kits.

Oxidized Cellulose and Plain Gauze: The Physical Baseline

At the quiet end sit the physical agents. Oxidized regenerated cellulose promotes clotting largely by physical and mild chemical action at the wound surface. Plain gauze itself contributes absorption and a pressure interface. That is why, in at least one controlled study, advanced dressings failed to beat it (more on that below). Remember this baseline whenever a product page implies the chemistry does all the work. Pressure and packing do much of the work; the agent is an accelerator.

The pattern to remember: cascade-dependent vs cascade-independent, mineral vs biologic, storage-sensitive vs shelf-stable. Those three axes predict real-world behavior better than any brand name.

The Evidence Tiers: CoTCCC-Recommended vs FDA-Cleared vs Just Claimed

Call it the Three-Tier Evidence Ladder: recommended by CoTCCC, cleared by FDA, or merely claimed by the seller. One boundary before we use it. The ladder is a filter for purchase decisions, not a clinical performance ranking. A Tier 1 listing does not mean “clots fastest,” and a Tier 2 clearance does not mean “outperforms the others.” What it ranks is how much independent verification stands behind the product. Most product pages skip this section, because it makes some products look ordinary. Don’t skip it.

The top tier is a CoTCCC recommendation. For tactical and prehospital trauma care, the reference point is the TCCC guidelines for hemorrhage control. The current guidelines name Combat Gauze, a kaolin-impregnated gauze, as the CoTCCC hemostatic dressing of choice. The listed alternatives are chitosan-based gauzes (Celox Gauze, ChitoGauze) and a minisponge product (XStat) for deep, narrow-tract junctional wounds. A place in that guideline means the product survived a formal evidence review by the committee whose recommendations drive military and much civilian trauma practice. Buying for tactical, EMS, or remote-industrial use? This list is your first filter.

Which tier actually binds you shifts with the account you are buying for. For a military or EMS account the CoTCCC list is the operative filter and clearance is assumed underneath it. For an industrial first-aid or retail-facing account, most of the catalogue has no CoTCCC listing at all, and clearance plus the labeled indication become the entire test. The tier also shifts with wound geometry: the guidelines reserve the minisponge format for deep, narrow tracts, so an account that will never see that geometry is paying for a listing that does not apply to its use.

One tier down sits FDA clearance. This is the 510(k) and product-code-FRO layer described above. Clearance tells you the device is substantially equivalent to a legal predicate and meets its special controls. In FDA’s 2022 proposal those controls include performance testing, shelf-life validation, sterilization validation, biocompatibility evaluation, descriptive information on the agent, and labeling requirements, with an antimicrobial-resistance risk assessment where the dressing contains an antimicrobial. Clearance does not tell you the product outperforms others; that is not what 510(k) measures. What it verifies is that you are dealing with a regulated manufacturer making a defined device, not a relabeled craft product.

Everything else is merely claimed. “Military grade,” “stops bleeding fast,” stock photos of tactical kits. No listing, no clearance, no mechanism named. Here the burden of proof sits entirely on the supplier. The verification section below is how you shift it.

Now the honesty layer, because all three tiers need it. FDA’s 2022 materials include the agency’s own literature review. Of the studies that met its inclusion criteria, four were relevant to dressings without thrombin and none to dressings with thrombin. One study found a hemostatic dressing produced a significantly shorter time to clot, with no serious complications. Two studies reported mixed results on survival in combat situations. The agency’s own summary: these dressings appear to improve clotting time compared with non-hemostatic dressings, but the impact on survival was inconclusive, and the review found no significant safety difference between the dressings and controls.

An earlier 2011 study indexed on PubMed pushed harder in the same direction. Advanced hemostatic dressings were compared against conventional gauze in an injury model resembling a care-under-fire scenario, and they did not perform better. Later work and guideline updates kept hemostatic dressings in the algorithms, but as an adjunct to well-done wound packing and pressure, not a replacement for technique. If a supplier’s pitch implies the dressing compensates for poor packing, that pitch is wrong.

Types and Formats

The same agent arrives in different carriers, and the carrier decides where you can use it. The FDA’s device description lists the forms neutrally: solid pads, sponges, granules, or gel. The procurement question is which geometry your wounds actually have:

• Z-folded gauze is the tactical standard. The Z-fold lets you feed the gauze into a deep wound cavity in one continuous motion during wound packing, without unrolling. Deep or junctional wounds (groin, axilla, neck base, where a tourniquet cannot go) call for exactly this format.
• Rolled gauze costs less per meter, works fine for surface wounds, and makes the right pressure layer over a packed wound. It is slower to pack a cavity with.
• Patches and sheets suit flatter, accessible wounds; they are common in clinical and surgical settings, usually individually packaged for a supply shelf rather than a belt pouch.
• Deep, narrow wound tracts are where the minisponge applicator (the XStat format) earns its place: a syringe-like device that injects small compressed sponges where gauze cannot be fed by hand. The TCCC guidelines reserve it for exactly that geometry.
• Finally, granules and powders with applicators, poured or injected into irregular cavities. Useful where gauze cannot conform, but loose agent in a wound raises cleanup questions, windy field conditions are unkind to powders, and FDA’s risk list flags what happens if granular material enters a blood vessel (more below).

A working kit usually pairs two formats on purpose: a Z-folded gauze for the deep-wound job you hope never happens, and a rolled or elastic pressure dressing for the bleeding you actually see. The formats are complements, not competitors. The Z-fold packs; the pressure wrap holds. Buy for both jobs, not for two brands of the same job. Whatever the format, expect individually sealed sterile packaging on any cleared product. And treat a broken seal the way the recall history says to: as a manufacturing defect, not a cosmetic issue.

The trap to avoid is buying a format for the wound you don’t have. A patch does not pack a junctional wound. Granules do not give you a pressure surface. Match carrier to wound geometry first, agent second.

For example, a police patrol kit and a mine-rescue cache can buy the identical agent and still need different carriers. The patrol kit carries one Z-folded gauze against a junctional wound it will probably never see, plus a rolled pressure dressing it will use for everything else. The mine cache stocks Z-fold by the carton and adds an applicator format, because crush injuries produce the irregular cavities that gauze conforms to poorly. Same chemistry, different purchase order.

How to Use One: Packing, Pressure, and the Three-Minute Hold

A hemostatic dressing fails more often from application than from chemistry, so the usage sequence deserves its own section. The steps below follow the TCCC guidelines; they summarize doctrine, and they are no substitute for hands-on training.

1. Find the source. Expose the wound and identify where the blood is actually coming from. The agent works at the bleeding vessel, not on top of pooled blood.
2. Pack to the source. Feed the gauze into the wound cavity directly against the bleeding point, filling the cavity tightly. For compressible bleeding that a limb tourniquet cannot reach, the guidelines name Combat Gauze as the dressing of choice, with Celox Gauze or ChitoGauze as alternatives and XStat for deep, narrow-tract junctional wounds.
3. Hold direct pressure for at least 3 minutes. This is the step people skip, and it is written into the guidelines explicitly: hemostatic dressings should be applied with at least 3 minutes of direct pressure (optional for XStat). The agent needs contact time with the vessel while the clot forms.

4. If it fails, do not layer wishful thinking. The guidelines state that each dressing works differently, so if one fails to control bleeding, it may be removed and a fresh dressing of the same type or a different type applied. The exception is XStat: it is not to be removed in the field; additional XStat, other hemostatic adjuncts, or trauma dressings go on top of it.
5. Secure the work. Once bleeding is controlled, hold everything in place with a pressure dressing — the Israeli-bandage class of device — wrapped firmly over the packed wound. The pressure dressing does not replace the manual hold during active bleeding; it preserves it afterward.

Two situational notes from the same guidelines. Where the bleeding site can take a junctional tourniquet, apply it immediately and do not delay — use hemostatic dressings with direct pressure while it is being readied or when one is not available. And for external bleeding of the head and neck where wound edges can be re-approximated, the iTClamp is a primary option, with the wound packed first where appropriate — plus airway monitoring, because an expanding hematoma in the neck is an airway problem.

Notice what the sequence assumes: the dressing is one layer in a technique. Packing quality, pressure duration, and the securing wrap decide the outcome as much as the agent does.

Take the case the guidelines are written around: a groin wound where a limb tourniquet has nowhere to sit. You expose the wound, feed the gauze in until it is packed tight against the bleeding vessel, and hold three minutes timed on a watch rather than judged by feel. Then the pressure wrap goes over the pack. If blood comes through it, the guidelines permit removing that dressing and packing fresh — which is the step most kits are not stocked to allow, because they were built with exactly one hemostatic dressing in them.

Safety and Failure Modes: What the FDA Risk List Tells You

The FDA’s 2022 classification materials include something rare in regulatory documents: a plain list of the identified risks for this device type, each paired with its mitigation measures. Read as a buyer, the list is a map of how these products fail.

• Uncontrolled bleeding — the device does not stop bleeding under anticipated conditions, or it is used incorrectly. Mitigation: material characterization, performance testing, shelf-life validation, labeling. Buyer translation: indications and instructions are not decoration; a degraded or misapplied dressing is a failed dressing.
• Infection — inadequate sterilization, inadequate viral inactivation of animal-derived materials, or broken packaging integrity. Mitigation: sterilization testing and validation, shelf-life validation, risk management for animal-derived materials.
• Foreign body reaction from a retained device — nonabsorbable hemostat material not completely removed from the wound can trigger a sustained inflammatory response, producing a pseudo mass that requires invasive diagnostic procedures to rule out tumor or abscess, and can cause chronic pain or compress vessels and nerves. This is the regulatory version of a field rule: account for what went into the wound, and make sure the receiving clinicians know it is there.
• Rebleeding after hemostasis — inadequate adhesive capacity of the hemostat, with coverage of the bleeding site compromised by exactly the conditions these products are marketed for: temperature extremes, poor lighting, and wind.
• Arterial or venous embolism and thrombosis — granular, powder, or reduced-dimension hemostat material entering a blood vessel. This risk is the strongest argument for preferring gauze carriers in deep wounds, and for treating loose-agent formats with respect.
• Antimicrobial resistance contribution — where a dressing contains an antimicrobial, the agency wants an AMR risk assessment, because the antimicrobial can select for resistant organisms.

The recall history in the same materials lands in the same place. FDA’s recall database query for product code FRO found eight recalled dressings without thrombin and four with licensed thrombin. The reasons are instructive: package seal integrity, wrong products packaged together, packaging sterility breaches, inappropriate claims, and non-sterile product shipped as sterile. The agency’s own conclusion: the recalls relate to manufacturing errors and do not suggest additional risks for the product class. For a buyer, that is the point — the catastrophic failures in this category have been factory failures, not chemistry failures. Which is why batch-level documentation appears in the verification checklist below.

None of this makes hemostatic dressings dangerous; it makes them a regulated device with known, managed failure modes. The discipline that the risk list encodes — follow the instructions for use, respect the shelf life, remove and account for the material, document the lot — is exactly the discipline a professional buyer should expect a manufacturer to document.

When to Use One — and When Plain Gauze Wins

Use a hemostatic dressing when all of these are true:

1. The bleeding is severe or the wound is deep — junctional wounds, deep lacerations, penetrating trauma — where direct surface pressure alone cannot reach the source.
2. You can pack the wound properly. The agent works at the bleeding vessel, not on top of pooled blood. A hemostatic gauze draped over a deep wound is an expensive bandage.
3. The situation justifies the cost and shelf-life management. These products cost many times more than plain gauze and expire.

Do not reach for one when the bleed is minor or moderate and accessible. The first-line answer to most bleeding is still direct pressure and a pressure dressing — the Israeli-bandage class of device. In the MARCH sequence that TCCC teaches, massive hemorrhage control starts with tourniquets and pressure; hemostatic dressings enter as the wound-packing layer, after those, not before them. FDA’s clinical background section says the same thing in regulatory language: when conventional methods such as compression fail, are ineffective, or are impractical, topical hemostatic devices may be used as an adjunct to local compression. Overbuying hemostatics for a kit that mostly sees minor wounds is a common budget leak; underspending on training to pack a wound is worse.

One spectrum note from the cleared indications: this single device type runs from over-the-counter products for minor cuts to emergency-only use for moderate-to-severe traumatic bleeding, and even the “severe” end is labeled as temporary control — a bridge in the evacuation chain, not the endpoint of care. The same words “hemostatic dressing” cover both ends of that spectrum, so check which end the specific product is cleared for. And keep the regulatory boundary in view: the device identification covers external use only. These are not implants and not a substitute for surgical hemostasis. Any supplier implying otherwise is outside the labeled use.

Finally, plan rotation before you buy, not after. Hemostatic dressings are consumables with a finite shelf life, and a kit that never rotates stock quietly fills up with expired product. Buy in quantities your training cycle can actually turn over, mark expiry dates on the kit card, and pull the oldest stock into training first. The cheapest hemostatic dressing is the one that is still in date on the day you need it.

Where that line falls varies with the conditions you are equipping for. Under short transport times to definitive care, the boundary sits where the regulator puts it: an adjunct for when compression fails or is impractical. Stretch the evacuation window and the same kit faces a longer hold on a single wound, which changes the quantity question before it changes the product question. Storage conditions move the line too — the risk list names temperature extremes, poor lighting and wind as the conditions under which adhesion and coverage fail, and those are field conditions, not warehouse ones.

How to Verify Before You Buy

For procurement, the Three-Tier Evidence Ladder plus the FDA risk list turn into a checklist. Seven questions, all answerable with documents:

1. What is the active agent, and which mechanism family is it? Kaolin, chitosan, MPH, thrombin, oxidized cellulose — the answer should name one of the families from this guide. If the supplier cannot name it, stop there.
2. Is it FDA-cleared? Ask for the 510(k) number and look up the product code — FRO for this device type. “Registered” is not “cleared.”
3. Is it on the CoTCCC recommended list (if you buy for tactical/EMS use)? The guidelines are public; check the current version, not a screenshot in a sales deck.
4. What is the shelf life and the storage envelope? Shelf-life validation is one of FDA’s special controls for this device type, so the data exists — get the number in writing, with the storage conditions that number assumes.
5. Where are the sterilization validation and biocompatibility evaluation? Both are special-control mitigation measures; a regulated manufacturer has them on file. If the dressing contains an antimicrobial, add the AMR risk assessment to the request.
6. What does the recall database show? FDA’s recall database is public and searchable by product code. The category’s recall history is manufacturing-side — seals, sterility, packaging — so the real question is whether this manufacturer shows up in it, and what changed afterward.
7. Can they supply traceable batch documentation — certificate of analysis per lot — the same way you would expect for any regulated consumable?

Notice the pattern in the answers you receive: a real manufacturer answers these seven questions with documents, a reseller answers with adjectives. And if you are buying OEM or private label, add one more question — whose 510(k) the product ships under, because the clearance belongs to a named legal manufacturer, and your label does not inherit it automatically.

For example, put question two to two suppliers and the answers separate them immediately. One returns a 510(k) number you can look up yourself against product code FRO. The other answers “FDA approved factory” — which is neither a number nor the right word, because this device type reaches the market by clearance, not by approval, and a registered facility is not a cleared device. You have not learned whether the product is compliant; you have learned that the person selling it cannot tell the two apart.

We manufacture kaolin and chitosan hemostatic gauze ourselves, so we sit on the supplier side of this table — which is exactly why we recommend you ask us these seven questions too. For bulk sourcing and OEM/private-label hemostatic gauze, see our kaolin hemostatic gauze manufacturer page.

Frequently Asked Questions

1. Is hemostatic gauze the same as regular gauze?

No. Regular gauze is a passive carrier: it absorbs blood and gives you something to press with. Hemostatic gauze carries an active agent — kaolin, chitosan, or another clotting accelerator — that interacts with the clotting process at the wound. Same fabric, different device. That difference is also why the two sit in different regulatory and price tiers: plain gauze is a commodity dressing, while hemostatic gauze is a cleared medical device with an active mechanism.

2. When should you use a hemostatic dressing?

For severe or deep bleeding that direct pressure cannot reach — junctional wounds (groin, armpit, neck base), deep lacerations, penetrating trauma — and only alongside proper wound packing and pressure, including the three-minute direct-pressure hold after packing. The control it provides is temporary: a bridge to definitive care, not a substitute for it. For minor accessible bleeding, direct pressure and a pressure dressing come first.

3. Is kaolin gauze the same as QuikClot?

QuikClot is a brand; kaolin is an agent. The widely fielded QuikClot Combat Gauze is a kaolin-impregnated gauze, but other manufacturers make kaolin gauze too, and QuikClot’s own earlier products used different agents (the original was a zeolite granule). Compare agent and evidence tier, not the trademark.

Related Articles

1. Hemostatic Dressing vs Gauze: Where the Extra Cost Actually Goes — the head-to-head on performance and price.
2. Combat Gauze vs QuikClot: Same Shelf, Different History — what the two best-known names actually contain.
3. What Is TCCC? The Guidelines Behind Modern Bleeding Control — the framework that decides which products make the recommended list.
4. Israeli Bandage vs Tourniquet: Two Steps, Not Two Options — where pressure dressings and tourniquets fit before hemostatics enter the sequence.

Resources & References

1. U.S. Food and Drug Administration — Classification of Topical Hemostatic Wound Dressings, General and Plastic Surgical Devices Advisory Panel Meeting, October 2022
2. Committee on Tactical Combat Casualty Care (CoTCCC) — TCCC Guidelines 2026
3. Watters JM et al. — Advanced hemostatic dressings are not superior to gauze for care under fire scenarios (2011)
4. ScienceDirect Topics — Hemostatic Dressing overview

Related commercial page: For a commercial sourcing page, review Rusun TacMed kaolin hemostatic gauze.